BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 29, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 1998

View Archived Issues

Medtronic announces another merger agreement

Read More

The Medicines Company begins phase III testing of Hirulog in heart attack patients

Read More

Immune Response receives broader patent protection for RA vaccine technology

Read More

Micrologix Biotech initiates phase I trial in U.S. with MBI-226

Read More

MGI Pharma expands prostate cancer study with MGI-114

Read More

Phase II trial of diabetic neuropathy Rx commenced by Myelos

Read More

Toray discloses new epsilon opioid receptor ligands

Read More

New antitumor series developed at Daiichi

Read More

Carbostyril compounds useful for arteriosclerosis and thrombosis

Read More

Wide series of adenosine kinase inhibitors undergoing evaluation at Abbott

Read More

News from ASH: lisofylline in BMT

Read More

Orally bioavailable anti-HIV peptides described in patent literature by Japan Energy

Read More

In vitro and clinical study results support development of nitazoxanide for H. pylori infection

Read More

Preliminary indications support safety and efficacy of 90Y-labeled lintuzumab in AML

Read More

Pfizer produces novel erythromycins using precursor-directed biosynthetic technology

Read More

Broad-spectrum, water-soluble antiviral agent produced by Streptomyces discovered in Japan

Read More

New imaging agent using AnorMED technology begins phase III trials

Read More

Avigen presents results of preclinical testing of hemophilia gene therapy and plans clinical trials

Read More

HBV DNA vaccine elicits protective immune response in humans for first time

Read More

Combination tablet that eases pill burden in HIV therapy now available in Canada

Read More

ImClone's anti-KDR antibody, a novel angiogenesis inhibitor, featured at ASH

Read More

Idec further defines clinical usage of IDEC-Y2B8

Read More

Canadian approval obtained for first chickenpox vaccine

Read More

The FDA approves lamivudine for the treatment of chronic HBV

Read More

Thalidomide evaluated for toxic epidermal necrolysis and found detrimental

Read More

Biological activity of ZD-7944 characterized in vitro and in animals

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 28, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing